Get the Stockscreener App
5.97
4.74%
0.27
After Hours:
5.97
Genfit Adr stock is traded at $5.97, with a volume of 30,748.
It is up +4.74% in the last 24 hours and up +37.56% over the past month.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
See More
Previous Close:
$5.70
Open:
$5.99
24h Volume:
30,748
Relative Volume:
3.10
Market Cap:
$297.94M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-8.1324
EPS:
-0.7341
Net Cash Flow:
-
1W Performance:
+19.64%
1M Performance:
+37.56%
6M Performance:
+67.70%
1Y Performance:
+82.57%
1-Day Range:
$5.70
$6.05
1-Week Range:
$5.08
$6.05
52-Week Range:
$2.8935
$6.05
Genfit Adr Stock (GNFT) Company Profile
Genfit Adr Stock (GNFT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-23-20 | Upgrade | Stifel | Hold → Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Underperform |
| May-13-20 | Downgrade | Kepler | Buy → Reduce |
| May-12-20 | Downgrade | Barclays | Overweight → Equal Weight |
| May-12-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-29-19 | Reiterated | B. Riley FBR | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Apr-24-19 | Initiated | SVB Leerink | Outperform |
| Apr-22-19 | Initiated | Barclays | Overweight |
View All
Genfit Adr Stock (GNFT) Latest News
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Move Higher in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Decrease Friday - MSN
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Trend Slightly Higher in Wednesday Trading - MSN
GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis - GlobeNewswire Inc.
Ipsen reçoit des avis positifs du CHMP pour Iqirvo® (elafibranor) dans la cholangite biliaire primitive et Kayfanda® (odévixibat) dans le syndrome d'Alagille, deux maladies rares du foie cholestatiques - GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Open Week Sharply Higher in Monday Trading - MSN
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial - GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading - MSN
Genfit: New EASL-EASD-EASO guidelines include NIS2+TipRanks.com - TipRanks
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading - MSN
GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH - GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading - MSN
GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo® for Primary Biliary ... - GlobeNewswire
GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary Cholangitis - GlobeNewswire Inc.
GENFIT: Historic Milestone Achieved with U.S. FDA - GlobeNewswire
Home / Today's Market - InvestorPlace
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading - MSN
Is Genfit (GNFT) Stock a Solid Choice Right Now - Yahoo Movies UK
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading - MSN
GENFIT to Present Latest ACLF Research at EASL Congress™ 2024 - GlobeNewswire Inc.
GENFIT: May 22, 2024 Combined Shareholders Meeting Results - GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Climb Higher in Wednesday Trading - MSN
GENFIT Reports First Quarter 2024 Financial Information - GlobeNewswire Inc.
GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023) - GlobeNewswire Inc.
GENFIT : Assemblée Générale Mixte du 22 mai 2024 — modalités de mise à disposition des documents préparatoires - GlobeNewswire Inc.
GENFIT : Mise à disposition du Document d’Enregistrement Universel 2023 et du Rapport Annuel Form 20-F 2023 - GlobeNewswire Inc.
GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update - GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Start Week Higher - MSN
Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine - Ipsen
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease - Ipsen
All You Need to Know About Flex (FLEX) Rating Upgrade to Strong Buy - Zacks Investment Research
Can GENFIT S.A. Unsponsored ADR (GNFT) Climb 79% to Reach the Level Wall Street Analysts Expect? - Yahoo New Zealand News
Ipsen und GENFIT schließen im Rahmen einer langfristigen globalen Partnerschaft eine exklusive Lizenzvereinbarung für Elafibranor ab, ein Phase-III-Asset, das für die Behandlung von primärer biliärer Cholangitis geprüft wird - businesswire.com
Exclusive Licensing Agreement with GENFIT | Ipsen Global - Ipsen
Intercept (ICPT) Posts New Positive Results on NASH Drug - Yahoo Movies UK
Intercept Down on Postponement of AdCom Meet for NASH Drug - Yahoo Movies UK
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Sh - Benzinga
The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, 3 Biotechs To IPO - Yahoo Finance
The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana - Yahoo Finance
Genfit (GNFT) Stock Price, News & AnalysisNASDAQ - MarketBeat
The Daily Biotech Pulse: Hookipa To Debut, Mustang Bio Skyrockets, AngioDynamics Sheds PortfolioiShare - Benzinga
Genfit Adr Stock (GNFT) Financials Data
There is no financial data for Genfit Adr (GNFT). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):